EUVIMEDEUVIMED entdecken
Crossref

C-reactive Protein, Genetic Susceptibility, and the Long-Term Risk of Venous Thromboembolism in Patients with Past Cancer

C-reaktives Protein, genetische Suszeptibilität und das Langzeitrisiko für venöse Thromboembolien bei Patient:innen mit durchgemachtem Krebs

Yunlong Guan, Zeyu Gan, Si Li iD, Xi Cao, Ao Zeng, Jing Li, Wei Gong, Jun Deng, Xingjie Hao

Thrombosis and Haemostasis · 01.10.2025 · 125 (10) · 1038-1047

DOI: 10.1055/a-2495-1350 ↗

Auf einen Blick

Bei 27.806 Krebsüberlebenden war ein höheres CRP mit einem höheren VTE-Risiko verbunden. Bei hohem genetischem Risiko war der Zusammenhang stärker.

Fragestellung

Besteht bei Krebsüberlebenden ein Zusammenhang zwischen CRP und dem langfristigen Risiko für venöse Thromboembolien, und wird er durch genetische Suszeptibilität beeinflusst?

Methode

Kohortenstudie mit Cox-Regression in der UK Biobank; Analyse von CRP-Quartilen, Kaplan-Meier-Kurven und restricted cubic spline.

Ergebnisse

27.806 Teilnehmende mit Krebsdiagnose zu Baseline; 1.151 VTE-Ereignisse in 344.636 Personenjahren. Gegenüber Q1: Q2 HR 1,20 (95 %-KI 0,99–1,44), Q3 1,25 (1,04–1,50), Q4 1,51 (1,25–1,82).

Schlussfolgerung der Autor:innen

CRP kann als prädiktiver Biomarker für das VTE-Risiko bei Krebsüberlebenden dienen, besonders bei hohem genetischem Risiko.

Kernaussagen

  • Höheres CRP war mit höherem VTE-Risiko verbunden.
  • Q4 vs. Q1: HR 1,51 (95 %-KI 1,25–1,82).
  • Bei hohem genetischem Risiko war der Zusammenhang stärker.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.10.2025. Verfasst von Yunlong Guan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, …. Hauptthemen laut MEDLINE: Venous Thromboembolism, C-Reactive Protein, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Fundamental Research Funds for School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, National Natural Science Foundation of China, Knowledge Innovation Special Project of Wuhan.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several studies have indicated that C-reactive protein (CRP) level is associated with the risk of venous thromboembolism (VTE) in the general population. However, CRP appears to be unrelated to VTE events in patients newly diagnosed with cancer. As the survival time of cancer patients increases, the effect of CRP on the long-term risk of VTE may change. We aimed to investigate the association between CRP and VTE in cancer survivors and further assess the modification effect of genetic susceptibility. The Cox proportional hazards model was used to evaluate the association between CRP levels and VTE risk as well as to investigate the joint effect of CRP and genetic susceptibility. The Kaplan-Meier curve and restricted cubic spline were used to visualize the relationship between CRP and VTE. This study included 27,806 participants with cancer diagnosis at baseline in the UK Biobank. Over a follow-up period of 344,636 person-years, a total of 1,151 VTE events were recorded. Participants were divided into four groups based on CRP level quartiles. The adjusted hazard ratios (95% CIs) of Q1, Q2, Q3, and Q4 were 1.00, 1.20 (0.99–1.44), 1.25 (1.04–1.50), and 1.51 (1.25–1.82), respectively. For those with high genetic risk of VTE, high CRP had an additional increased risk for VTE. CRP can be used as a predictive biomarker for VTE risk in cancer survivors, especially in those with high genetic risk. Future research can explore whether prevention and treatment strategies for VTE can be developed based on CRP for cancer survivors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismC-Reactive ProteinNeoplasmsHumansMaleFemaleMiddle AgedGenetic Predisposition to DiseaseRisk FactorsAgedRisk AssessmentAdultProportional Hazards ModelsBiomarkersTime FactorsCancer SurvivorsUnited Kingdom

Substanzen

C-Reactive ProteinBiomarkers

Autor:innen und Institutionen

  • Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Oncology, Xiang yang Central Hospital, Hubei University of Arts and Science, Xiang yang, Hubei, China.
  • Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

ORCID-Profile: Si Li

Förderung

  • Fundamental Research Funds for School of Public Health, Tongji Medical College, Huazhong University of Science and Technology
  • National Natural Science Foundation of China
  • Knowledge Innovation Special Project of Wuhan
  • Ministry of Science and Technology of the People's Republic of China

Zitieren

APA

Guan, Y., Gan, Z., Li, S., Cao, X., Zeng, A., Li, J., Gong, W., Deng, J., & Hao, X. (2025). C-reactive Protein, Genetic Susceptibility, and the Long-Term Risk of Venous Thromboembolism in Patients with Past Cancer. Thrombosis and Haemostasis, 125(10), 1038-1047. https://doi.org/10.1055/a-2495-1350

Vancouver

Guan Y, Gan Z, Li S, Cao X, Zeng A, Li J, et al. C-reactive Protein, Genetic Susceptibility, and the Long-Term Risk of Venous Thromboembolism in Patients with Past Cancer. Thrombosis and Haemostasis. 2025;125(10):1038-1047. doi:10.1055/a-2495-1350

BibTeX
@article{Guan2025,
  author = {Guan, Yunlong and Gan, Zeyu and Li, Si and Cao, Xi and Zeng, Ao and Li, Jing and Gong, Wei and Deng, Jun and Hao, Xingjie},
  title = {C-reactive Protein, Genetic Susceptibility, and the Long-Term Risk of Venous Thromboembolism in Patients with Past Cancer},
  journal = {Thrombosis and Haemostasis},
  year = {2025},
  volume = {125},
  number = {10},
  pages = {1038--1047},
  doi = {10.1055/a-2495-1350}
}
Kostenlos starten →